Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mabpharm Limited ( (HK:2181) ) has provided an update.
Mabpharm Limited reported its financial results for the year ended December 31, 2024, showing a significant increase in revenue by 196.3% to RMB 258,228,000 compared to the previous year. Despite the revenue growth, the company recorded a loss before tax of RMB 127,947,000, which is an improvement from the previous year’s loss. The results reflect increased selling and distribution expenses and a reduction in research and development expenses, impacting the company’s financial performance and market positioning.
More about Mabpharm Limited
Mabpharm Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative drugs. The company is listed on the Hong Kong Stock Exchange under the stock code 2181.
YTD Price Performance: 96.43%
Average Trading Volume: 110,650
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.27B
Learn more about 2181 stock on TipRanks’ Stock Analysis page.